Changes

The long-term consequences of the HPV vaccine are unknown as there have not been any long-term studies.  Children in the 9-year-old age group have been monitored for 18 months, and there have been no studies of possible longer-term risks of the vaccine.  Between July 2006 and January 2007, there were 82 reports of adverse events filed with the Vaccine Adverse Event Reporting System ([[VAERS]]) following the receipt of the vaccine.

The long-term consequences of the HPV vaccine are unknown as there have not been any long-term studies.  Children in the 9-year-old age group have been monitored for 18 months, and there have been no studies of possible longer-term risks of the vaccine.  Between July 2006 and January 2007, there were 82 reports of adverse events filed with the Vaccine Adverse Event Reporting System ([[VAERS]]) following the receipt of the vaccine.

A study published February 28, 2007 in the Journal of the American Medical Association (JAMA) <ref>JAMA 297(8):813-819, February 28, 2007</ref> disclosed that about 3% of women are infected in their lifetime by the particular types of HPV (Types 6, 11, 16, 18) targeted by the vaccine. ''Time'' magazine calls HPV "the most common sexually transmitted infection".<ref>[http://www.time.com/time/nation/article/0,8599,1206813,00.html  Defusing the War Over the "Promiscuity" Vaccine]</ref>

A study published February 28, 2007 in the Journal of the American Medical Association (JAMA) <ref>JAMA 297(8):813-819, February 28, 2007</ref> disclosed that about 3% of women are infected in their lifetime by the particular types of HPV (Types 6, 11, 16, 18) targeted by the vaccine. <!-- ''this assertion is dubious; the latest figures from CDC [http://www.cdc.gov/std/stats/trends2006.htm here] say that chlamydia is the most common; Time may be applying different critera, which should be stated.''  ''Time'' magazine calls HPV "the most common sexually transmitted infection".<ref>[http://www.time.com/time/nation/article/0,8599,1206813,00.html  Defusing the War Over the "Promiscuity" Vaccine]</ref>-->

 

Merck manufactures the HPV vaccine ("Gardasil") and sells it for $360 ($120 per shot in a three-shot series).  Its package insert explains the limitations of the vaccine and describes its testing for safety and efficacy.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref>

Merck manufactures the HPV vaccine ("Gardasil") and sells it for $360 ($120 per shot in a three-shot series).  Its package insert explains the limitations of the vaccine and describes its testing for safety and efficacy.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref>